GeoVax Labs Company Profile (OTCMKTS:GOVX)

About GeoVax Labs (OTCMKTS:GOVX)

GeoVax Labs logoGeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:GOVX
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.88 million
  • Outstanding Shares: 66,913,000
Average Prices:
  • 50 Day Moving Avg: $0.03
  • 200 Day Moving Avg: $0.04
  • 52 Week Range: $0.03 - $0.08
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.61
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $1.26 million
  • Price / Sales: 2.28
  • Book Value: ($0.03) per share
  • Price / Book: -1.65
  • EBIDTA: ($2,440,000.00)
  • Net Margins: -195.32%
  • Return on Assets: -383.66%
  • Current Ratio: 1.43%
  • Quick Ratio: 1.43%
  • Average Volume: 335,758 shs.
  • Beta: -0.08

Frequently Asked Questions for GeoVax Labs (OTCMKTS:GOVX)

What is GeoVax Labs' stock symbol?

GeoVax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How were GeoVax Labs' earnings last quarter?

GeoVax Labs Inc. (OTCMKTS:GOVX) issued its quarterly earnings data on Wednesday, November, 19th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. View GeoVax Labs' Earnings History.

When will GeoVax Labs make its next earnings announcement?

GeoVax Labs is scheduled to release their next quarterly earnings announcement on Friday, November, 10th 2017. View Earnings Estimates for GeoVax Labs.

Who are some of GeoVax Labs' key competitors?

Who are GeoVax Labs' key executives?

GeoVax Labs' management team includes the folowing people:

  • David A. Dodd, Independent Chairman of the Board
  • Robert T. McNally Ph.D., President, Chief Executive Officer, Director
  • Mark W. Reynolds CPA, Chief Financial Officer, Corporate Secretary
  • Harriet Latham Robinson Ph.D., Chief Scientific Officer, Director
  • Randal D. Chase Ph.D., Director
  • Dean G. Kollintzas, Independent Director
  • John N. Spencer Jr., CPA, Independent Director

How do I buy GeoVax Labs stock?

Shares of GeoVax Labs can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GeoVax Labs' stock price today?

One share of GeoVax Labs stock can currently be purchased for approximately $0.04.

MarketBeat Community Rating for GeoVax Labs (OTCMKTS GOVX)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  27
MarketBeat's community ratings are surveys of what our community members think about GeoVax Labs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GeoVax Labs (OTCMKTS:GOVX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GeoVax Labs (OTCMKTS:GOVX)
No equities research coverage for this company has been tracked by


Earnings History for GeoVax Labs (OTCMKTS:GOVX)
Earnings by Quarter for GeoVax Labs (OTCMKTS:GOVX)
Earnings History by Quarter for GeoVax Labs (OTCMKTS GOVX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/19/2014($0.03)($0.02)ViewN/AView Earnings Details
8/22/2014($0.03)($0.03)ViewN/AView Earnings Details
5/2/2014($0.03)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GeoVax Labs (OTCMKTS:GOVX)
Current Year EPS Consensus Estimate: $-0.04 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS


Dividend History for GeoVax Labs (OTCMKTS:GOVX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for GeoVax Labs (OTCMKTS:GOVX)
Insider Ownership Percentage: 4.40%
Insider Trades by Quarter for GeoVax Labs (OTCMKTS:GOVX)
Insider Trades by Quarter for GeoVax Labs (OTCMKTS:GOVX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/5/2015Randal D ChaseDirectorBuy10,000$0.19$1,900.00View SEC Filing  
4/23/2015Mark ReynoldsCFOBuy30,000$0.17$5,100.00View SEC Filing  
4/20/2015Randal D ChaseDirectorBuy30,000$0.17$5,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GeoVax Labs (OTCMKTS:GOVX)
Latest Headlines for GeoVax Labs (OTCMKTS:GOVX)
DateHeadline logoGeoVax Provides Update on its Zika Vaccine Development - September 18 at 6:41 PM logoGeoVax Presents Preliminary Data for Cancer Vaccine - August 30 at 4:32 PM logoGeoVax Presents Zika Vaccine Data at Scientific Conference - August 30 at 4:32 PM logoGeoVax to Present at Upcoming Immuno-Oncology Conference - August 22 at 7:42 PM logoGeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine - July 24 at 9:07 PM logoGeoVax Reports Promising Results for Lassa Fever Vaccine - July 10 at 7:06 PM logoGeoVax Awarded NIH Grant for Zika Vaccine - June 19 at 12:47 PM logoGeoVax to Conduct Partnering Meetings During BIO International Convention June 19-22 - June 7 at 10:50 AM logoGeoVax Presents Data on Novel Zika Vaccine - June 5 at 10:48 AM logoAtlanta biotech firm GeoVax raises $1 million in stock sale - May 9 at 12:39 PM logoGeoVax Reports 2017 First Quarter Financial Results and Development Program Updates - May 8 at 5:15 PM logoGeoVax to Present Zika Vaccine Data at the 20th Annual Conference on Vaccine Research - April 10 at 11:19 AM logoGeoVax Awarded $658,000 NIH Grant for its HIV Vaccine Program - April 3 at 11:59 AM logoGeoVax Reports on Vaccine Development Progress - March 27 at 11:25 AM logoGeoVax Reports Promising Results for Zika Vaccine - March 20 at 7:14 PM logoGeoVax Announces Collaboration with American Gene Technologies for HIV Functional Cure - March 14 at 12:20 PM logoGOVX: Multiple Progress Made in the Last Two Months - February 14 at 6:41 PM logoGeoVax Media and Presentation Update - February 2 at 6:07 PM logoBRIEF-GeoVax announces initiation of HIV Human Clinical Trial - January 23 at 11:20 AM logoGeoVax Announces Initiation of HIV Human Clinical Trial - January 23 at 11:20 AM logoGeoVax to Collaborate with Georgia State University on Development of Therapeutic Hepatitis B Vaccine - January 17 at 9:20 AM logoGeoVax and Burnet Institute to Join Forces to Develop Malaria Vaccine - January 9 at 4:20 PM logoZika vaccine developer names new chief scientific officer - January 3 at 11:57 AM logoGeoVax Announces Appointment of Farshad Guirakhoo, PhD as Chief Scientific Officer - December 14 at 6:11 PM logoGeoVax to Conduct Investor and Partnering Meetings During 35th Annual J.P. Morgan Healthcare Conference - December 7 at 10:40 AM logoGeoVax to Present at Keystone Symposia on Hemorrhagic Fever Viruses - December 5 at 11:20 AM logoGeoVax Observes World AIDS Day - December 1 at 10:37 AM logoGOVX: Update on Third Quarter Financials - November 21 at 10:23 AM logoGeoVax and ViaMune to Collaborate on Cancer Immunotherapy Program - November 7 at 5:31 PM logoGeoVax HIV Vaccine Clinical Data Presented At HIVR4P Conference - October 20 at 5:19 PM logoGeoVax to Present at Upcoming Scientific Conferences on Its Hemorrhagic Fever and Zika Vaccine Programs - October 3 at 9:54 AM logoGOVX: Progress Made to Advance its Vaccine Programs - August 29 at 5:11 PM logoGeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update - August 5 at 5:24 PM logoUPDATE - GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial - July 1 at 9:00 AM logo9:01 am GeoVax announces VNIH filed an INDA w/ the FDA for the conduct of the next human clinical trial of its preventive HIV vaccine - June 30 at 9:01 AM logo9:01 am GeoVax announces VNIH filed an INDA w/ the FDA for the conduct of the next human clinical trial of its preventive HIV vaccine - June 30 at 9:01 AM logoGeoVax Discusses Zika Vaccine Development at American Society for Virology's 35th Annual Meeting - June 21 at 2:30 PM logoGEOVAX LABS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of - June 16 at 10:10 AM logoGOVX: GeoVax: Entering into HBV Market - June 7 at 11:15 AM logoGOVX: Update on First Quarter Financials - June 1 at 10:00 AM logoGeoVax Recognizes National Black HIV/AIDS Awareness Day / Bringing Attention to Minority Health Disparities in HIV/AIDS and the Need for a Vaccine - February 5 at 2:10 PM logoIndian Pharma Files For Patent For First Zika Vaccine - February 3 at 1:38 PM



GeoVax Labs (GOVX) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff